SARILUMAB DOSE REDUCTION IN AN OPEN-LABEL EXTENSION STUDY IN RA PATIENTS WITH INADEQUATE RESPONSE TO TNF INHIBITORS

被引：1
|
作者：
Fleischmann, R. [1 ]
Hrycaj, P. [2 ]
van Hoogstraten, H. [3 ]
Mangan, E. K. [4 ]
Lin, Y. [3 ]
Jayawardena, S. [3 ]
Burmester, G. R. [5 ,6 ]
机构：
[1] Univ Texas Southwestern Med Ctr Dallas, Metroplex Clin Res Ctr, Dallas, TX 75390 USA
[2] Poznan Univ Med Sci, Dept Rheumatol & Clin Immunol, Poznan, Poland
[3] Sanofi Genzyme, Bridgewater, MA USA
[4] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA
[5] Free Univ, Charite Univ Med Berlin, Berlin, Germany
[6] Humboldt Univ, Berlin, Germany
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2017年 / 76卷
关键词：
D O I：
10.1136/annrheumdis-2017-eular.5155
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SAT0212
引用
收藏
页码：853 / 853
页数：1
相关论文
共 50 条
  • [41] Evaluating dose regimens of apomorphine, an open-label study
    A Kongkanand
    J Opanuraks
    K Tantiwongse
    N Choeypunt
    A Tantiwong
    T Amornvejsukit
    International Journal of Impotence Research, 2003, 15 : S10 - S12
  • [42] Evaluating dose regimens of apomorphine, an open-label study
    Kongkanand, A
    Opanuraks, J
    Tantiwongse, K
    Choeypunt, N
    Tantiwong, A
    Amornvejsukit, T
    INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 2003, 15 (Suppl 2) : S10 - S12
  • [43] Olanzapine optimal dose: Results of an open-label multicenter study in schizophrenic patients
    Ishigooka, J
    Murasaki, M
    Miura, S
    PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2000, 54 (04) : 467 - 478
  • [44] Inhaled mannitol in patients with cystic fibrosis: A randomised open-label dose response trial
    Teper, Alejandro
    Jaques, Anna
    Charlton, Brett
    JOURNAL OF CYSTIC FIBROSIS, 2011, 10 (01) : 1 - 8
  • [45] CLINICAL REMISSION OUTCOMES WITH SARILUMAB PLUS CSDMARDS IN ACTIVE, MODERATE-TO-SEVERE RA PATIENTS WITH INADEQUATE RESPONSE TO TUMOR NECROSIS FACTOR INHIBITORS
    Burmester, G.
    Hrycaj, P.
    Pacheco-Tena, C.
    van Hoogstraten, H.
    Mangan, E. K.
    Lin, Y.
    Bauer, D.
    Fay, J.
    Parrino, J.
    Kivitz, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 727 - 728
  • [46] Results of an open label dose response study of thalidomide in patients with advanced heart failure and elevated levels of TNF
    Bozkurt, B
    Chee, A
    Lee-Jackson, D
    Deswal, A
    Zeldis, JB
    Mann, DL
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 35 (02) : 172A - 173A
  • [47] Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study
    Feagan, Brian G.
    Panes, Julian
    Ferrante, Marc
    Kaser, Arthur
    D'Haens, Geert R.
    Sandborn, William J.
    Louis, Edouard
    Neurath, Markus F.
    Franchimont, Denis
    Dewit, Olivier
    Seidler, Ursula
    Kim, Kyung-Jo
    Selinger, Christian
    Padula, Steven J.
    Herichova, Ivona
    Robinson, Anne M.
    Wallace, Kori
    Zhao, Jun
    Minocha, Mukul
    Othman, Ahmed A.
    Soaita, Adina
    Visvanathan, Sudha
    Hall, David B.
    Boecher, Wulf O.
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2018, 3 (10): : 671 - 680
  • [48] OPEN-LABEL EXTENSION STUDY: TEZACAFTOR/IVACAFTOR, PATIENTS ≥ 12 YEARS WITH CYSTIC FIBROSIS
    Wainwright, C.
    Flume, P.
    Biner, Fischer R.
    Downey, D.
    Brown, C.
    Jain, M.
    Fischer, R.
    De Boeck, K.
    Campbell, D.
    Wang, X.
    Ahluwalia, N.
    Owen, C.
    RESPIROLOGY, 2020, 25 : 57 - 57
  • [49] PHASE 2 OPEN-LABEL EXTENSION STUDY WITH DONIDALORSEN TREATMENT IN PATIENTS WITH HEREDITARY ANGIOEDEMA
    Bordone, L.
    Riedl, M.
    Newman, K.
    Lui, C.
    Alexander, V.
    Schneider, E.
    Cohn, D.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2022, 129 : S33 - S33
  • [50] An open-label extension study of lurasidone in patients with schizophrenia previously randomized to lurasidone or risperidone
    Mattingly, G.
    Tocco, M.
    Cucchiaro, J.
    Xu, J.
    Pikalov, A.
    Loebel, A.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2014, 24 : S559 - S559
12345